Assembly Biosciences, Inc.
ASMBNASDAQHealthcare● Active
$22.56
$-0.35(-1.51%)
Market Cap$358464382
P/E Ratio—
52W High$39.71
52W Low$15.54
Assembly Biosciences, Inc. (ASMB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASMB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.54
Est. -$0.73 · +26.0%
Revenue
$0.01B
Est. $0.01B · -11.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
ASMB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.70 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.73 | -$0.54 | +26.0% | $0.01B | $0.01B | -11.4% |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$0.51 | $2.48 | +586.3% | $0.04B | $0.01B | +472.2% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.50 | -$0.72 | -44.0% | $0.01B | $0.01B | +44.6% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.65 | -$1.33 | -103.6% | $0.01B | $0.01B | +3.2% |
| ▲ Q2 FY2025 | May 8, 2025 | -$2.01 | -$1.17 | +41.8% | $0.01B | $0.01B | +27.0% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$1.75 | -$1.57 | +10.3% | $0.01B | $0.00B | +107.2% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$2.02 | -$1.51 | +25.3% | $0.01B | $0.01B | -2.9% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.54
EPS Est.
-$0.73
EPS Surpr.
+26.0%
Revenue
$0.01B
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
$2.48
EPS Est.
-$0.51
EPS Surpr.
+586.3%
Revenue
$0.04B
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.72
EPS Est.
-$0.50
EPS Surpr.
-44.0%
Revenue
$0.01B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$1.33
EPS Est.
-$0.65
EPS Surpr.
-103.6%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$1.17
EPS Est.
-$2.01
EPS Surpr.
+41.8%
Revenue
$0.01B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$1.57
EPS Est.
-$1.75
EPS Surpr.
+10.3%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$1.51
EPS Est.
-$2.02
EPS Surpr.
+25.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.21 | $0.29 | $0.35 | 1 |
| Q3 FY2027 | $-1.39 | $-1.14 | $-0.81 | 1 |
| Q2 FY2027 | $-1.38 | $-1.14 | $-0.80 | 1 |
| Q1 FY2027 | $-0.78 | $-0.64 | $-0.45 | 1 |
| Q4 FY2026 | $0.24 | $0.33 | $0.40 | 1 |
| Q3 FY2026 | $-0.85 | $-0.70 | $-0.50 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +26.0% | $31.36 | $30.93 | -1.37% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +586.3% | $27.52 | $27.51 | -0.04% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -44.0% | $31.20 | $32.07 | +2.79% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -103.6% | $18.86 | $19.43 | +3.02% |
| ▲ Q2 FY2025 | May 8, 2025 | +41.8% | $12.41 | $11.66 | -6.04% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +10.3% | $10.85 | $10.69 | -1.47% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +25.3% | $16.65 | $17.50 | +5.11% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +33.1% | $12.62 | $13.38 | +6.02% |
Q2 FY2026-1.37%
Report Date
May 7, 2026
EPS Beat/Miss
+26.0%
Price Before
$31.36
Price After
$30.93
Q1 FY2026-0.04%
Report Date
Mar 19, 2026
EPS Beat/Miss
+586.3%
Price Before
$27.52
Price After
$27.51
Q4 FY2025+2.79%
Report Date
Nov 10, 2025
EPS Beat/Miss
-44.0%
Price Before
$31.20
Price After
$32.07
Q3 FY2025+3.02%
Report Date
Aug 6, 2025
EPS Beat/Miss
-103.6%
Price Before
$18.86
Price After
$19.43
Q2 FY2025-6.04%
Report Date
May 8, 2025
EPS Beat/Miss
+41.8%
Price Before
$12.41
Price After
$11.66
Q1 FY2025-1.47%
Report Date
Mar 20, 2025
EPS Beat/Miss
+10.3%
Price Before
$10.85
Price After
$10.69
Q4 FY2024+5.11%
Report Date
Nov 7, 2024
EPS Beat/Miss
+25.3%
Price Before
$16.65
Price After
$17.50
Q3 FY2024+6.02%
Report Date
Aug 8, 2024
EPS Beat/Miss
+33.1%
Price Before
$12.62
Price After
$13.38
Avg Beat Reaction+0.37%
Avg Miss Reaction+2.91%
Beat Rate6 / 8 quarters
Largest Move-6.04% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASMB ends December
Assembly Biosciences, Inc. (ASMB) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.54 — beating the analyst consensus of $-0.73 by +26.0%. ASMB has beaten EPS estimates for 2 consecutive quarters. The next ASMB earnings date is expected around September 1, 2026.
Each quarter, investors track ASMB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASMB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASMB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASMB earnings · 5 questionsAssembly Biosciences, Inc.'s next earnings report is expected around September 1, 2026. ASMB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASMB historically reports after market close (AMC).
ASMB earnings datewhen is ASMB earningsASMB next earnings datewhen does ASMB report earningsASMB earnings calendar
▸ Source: FMP · Assembly Biosciences, Inc. SEC filings · US GAAP · Assembly Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026